Quick Answer
Akebia Therapeutics, Inc. reported Long Term Debt of $48.25 million for the year ending 2025.
- Akebia Therapeutics, Inc. showed an increase of +24.7% in Long Term Debt from 2024 to 2025.
- This data is from Akebia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $76.07 million | Q2 2020: $76.34 million | Q3 2020: $76.61 million | Q1 2021: $96.61 million | Q2 2021: $96.92 million | Q3 2021: $97.23 million | Q1 2023: $26.30 million | Q2 2023: $18.49 million | Q3 2023: $34.61 million | Q1 2024: $30.15 million | Q2 2024: $38.03 million | Q3 2024: $38.36 million | Q1 2025: $46.51 million | Q2 2025: $47.06 million | Q3 2025: $47.64 million.
- Over the full 7 years of available data (2019 to 2025), Akebia Therapeutics, Inc.'s Long Term Debt has declined by 36.3%.
- Historical annual values: Fiscal year 2025: $48.25 million | Fiscal year 2024: $38.69 million | Fiscal year 2023: $17.18 million | Fiscal year 2022: $34.08 million | Fiscal year 2021: $0.00 | Fiscal year 2020: $96.38 million | Fiscal year 2019: $75.81 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: